Stott, A. J., Maillard, M. C., Beaumont, V., Allcock, D., Aziz, O., Borchers, A. H., . . . Dominguez, C. (2021). Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease. ACS Med Chem Lett.
استشهاد بنمط شيكاغوStott, Andrew J., et al. "Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease." ACS Med Chem Lett 2021.
MLA استشهادStott, Andrew J., et al. "Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease." ACS Med Chem Lett 2021.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.